Network medicine framework for identifying drug-repurposing opportunities for COVID-19. 2021

Deisy Morselli Gysi, and Ítalo do Valle, and Marinka Zitnik, and Asher Ameli, and Xiao Gan, and Onur Varol, and Susan Dina Ghiassian, and J J Patten, and Robert A Davey, and Joseph Loscalzo, and Albert-László Barabási
Network Science Institute, Northeastern University, Boston, MA 02115.

The COVID-19 pandemic has highlighted the need to quickly and reliably prioritize clinically approved compounds for their potential effectiveness for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Here, we deployed algorithms relying on artificial intelligence, network diffusion, and network proximity, tasking each of them to rank 6,340 drugs for their expected efficacy against SARS-CoV-2. To test the predictions, we used as ground truth 918 drugs experimentally screened in VeroE6 cells, as well as the list of drugs in clinical trials that capture the medical community's assessment of drugs with potential COVID-19 efficacy. We find that no single predictive algorithm offers consistently reliable outcomes across all datasets and metrics. This outcome prompted us to develop a multimodal technology that fuses the predictions of all algorithms, finding that a consensus among the different predictive methods consistently exceeds the performance of the best individual pipelines. We screened in human cells the top-ranked drugs, obtaining a 62% success rate, in contrast to the 0.8% hit rate of nonguided screenings. Of the six drugs that reduced viral infection, four could be directly repurposed to treat COVID-19, proposing novel treatments for COVID-19. We also found that 76 of the 77 drugs that successfully reduced viral infection do not bind the proteins targeted by SARS-CoV-2, indicating that these network drugs rely on network-based mechanisms that cannot be identified using docking-based strategies. These advances offer a methodological pathway to identify repurposable drugs for future pathogens and neglected diseases underserved by the costs and extended timeline of de novo drug development.

UI MeSH Term Description Entries
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002522 Chlorocebus aethiops A species of CERCOPITHECUS containing three subspecies: C. tantalus, C. pygerythrus, and C. sabeus. They are found in the forests and savannah of Africa. The African green monkey is the natural host of SIMIAN IMMUNODEFICIENCY VIRUS and is used in AIDS research. African Green Monkey,Cercopithecus aethiops,Cercopithecus griseoviridis,Cercopithecus griseus,Cercopithecus pygerythrus,Cercopithecus sabeus,Cercopithecus tantalus,Chlorocebus cynosuros,Chlorocebus cynosurus,Chlorocebus pygerythrus,Green Monkey,Grivet Monkey,Lasiopyga weidholzi,Malbrouck,Malbrouck Monkey,Monkey, African Green,Monkey, Green,Monkey, Grivet,Monkey, Vervet,Savanah Monkey,Vervet Monkey,Savannah Monkey,African Green Monkey,Chlorocebus cynosuro,Green Monkey, African,Green Monkeys,Grivet Monkeys,Malbrouck Monkeys,Malbroucks,Monkey, Malbrouck,Monkey, Savanah,Monkey, Savannah,Savannah Monkeys,Vervet Monkeys
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000093485 COVID-19 Drug Treatment The use of DRUGS to treat COVID19 or its symptoms. COVID-19 Drug Therapy,COVID19 Drug Therapy,COVID19 Drug Treatment,Coronavirus Disease 2019 Drug Treatment,Coronavirus Disease-19 Drug Treatment,COVID 19 Drug Therapy,COVID 19 Drug Treatment,COVID-19 Drug Therapies,COVID19 Drug Therapies,COVID19 Drug Treatments,Coronavirus Disease 19 Drug Treatment,Drug Therapy, COVID-19,Drug Therapy, COVID19,Therapy, COVID-19 Drug,Therapy, COVID19 Drug,Treatment, COVID-19 Drug
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D014709 Vero Cells A CELL LINE derived from the kidney of the African green (vervet) monkey, (CHLOROCEBUS AETHIOPS) used primarily in virus replication studies and plaque assays. Cell, Vero,Cells, Vero,Vero Cell
D014764 Viral Proteins Proteins found in any species of virus. Gene Products, Viral,Viral Gene Products,Viral Gene Proteins,Viral Protein,Protein, Viral,Proteins, Viral
D016571 Neural Networks, Computer A computer architecture, implementable in either hardware or software, modeled after biological neural networks. Like the biological system in which the processing capability is a result of the interconnection strengths between arrays of nonlinear processing nodes, computerized neural networks, often called perceptrons or multilayer connectionist models, consist of neuron-like units. A homogeneous group of units makes up a layer. These networks are good at pattern recognition. They are adaptive, performing tasks by example, and thus are better for decision-making than are linear learning machines or cluster analysis. They do not require explicit programming. Computational Neural Networks,Connectionist Models,Models, Neural Network,Neural Network Models,Neural Networks (Computer),Perceptrons,Computational Neural Network,Computer Neural Network,Computer Neural Networks,Connectionist Model,Model, Connectionist,Model, Neural Network,Models, Connectionist,Network Model, Neural,Network Models, Neural,Network, Computational Neural,Network, Computer Neural,Network, Neural (Computer),Networks, Computational Neural,Networks, Computer Neural,Networks, Neural (Computer),Neural Network (Computer),Neural Network Model,Neural Network, Computational,Neural Network, Computer,Neural Networks, Computational,Perceptron
D049490 Systems Biology Comprehensive, methodical analysis of complex biological systems by monitoring responses to perturbations of biological processes. Large scale, computerized collection and analysis of the data are used to develop and test models of biological systems. Biology, Systems

Related Publications

Deisy Morselli Gysi, and Ítalo do Valle, and Marinka Zitnik, and Asher Ameli, and Xiao Gan, and Onur Varol, and Susan Dina Ghiassian, and J J Patten, and Robert A Davey, and Joseph Loscalzo, and Albert-László Barabási
January 2022, Briefings in bioinformatics,
Deisy Morselli Gysi, and Ítalo do Valle, and Marinka Zitnik, and Asher Ameli, and Xiao Gan, and Onur Varol, and Susan Dina Ghiassian, and J J Patten, and Robert A Davey, and Joseph Loscalzo, and Albert-László Barabási
January 2019, Cancer journal (Sudbury, Mass.),
Deisy Morselli Gysi, and Ítalo do Valle, and Marinka Zitnik, and Asher Ameli, and Xiao Gan, and Onur Varol, and Susan Dina Ghiassian, and J J Patten, and Robert A Davey, and Joseph Loscalzo, and Albert-László Barabási
January 2020, Frontiers in cell and developmental biology,
Deisy Morselli Gysi, and Ítalo do Valle, and Marinka Zitnik, and Asher Ameli, and Xiao Gan, and Onur Varol, and Susan Dina Ghiassian, and J J Patten, and Robert A Davey, and Joseph Loscalzo, and Albert-László Barabási
June 2021, Medicine in drug discovery,
Deisy Morselli Gysi, and Ítalo do Valle, and Marinka Zitnik, and Asher Ameli, and Xiao Gan, and Onur Varol, and Susan Dina Ghiassian, and J J Patten, and Robert A Davey, and Joseph Loscalzo, and Albert-László Barabási
March 2022, Pharmaceutics,
Deisy Morselli Gysi, and Ítalo do Valle, and Marinka Zitnik, and Asher Ameli, and Xiao Gan, and Onur Varol, and Susan Dina Ghiassian, and J J Patten, and Robert A Davey, and Joseph Loscalzo, and Albert-László Barabási
June 2023, Aging,
Deisy Morselli Gysi, and Ítalo do Valle, and Marinka Zitnik, and Asher Ameli, and Xiao Gan, and Onur Varol, and Susan Dina Ghiassian, and J J Patten, and Robert A Davey, and Joseph Loscalzo, and Albert-László Barabási
April 2021, Pharmaceutics,
Deisy Morselli Gysi, and Ítalo do Valle, and Marinka Zitnik, and Asher Ameli, and Xiao Gan, and Onur Varol, and Susan Dina Ghiassian, and J J Patten, and Robert A Davey, and Joseph Loscalzo, and Albert-László Barabási
December 2020, JAMIA open,
Deisy Morselli Gysi, and Ítalo do Valle, and Marinka Zitnik, and Asher Ameli, and Xiao Gan, and Onur Varol, and Susan Dina Ghiassian, and J J Patten, and Robert A Davey, and Joseph Loscalzo, and Albert-László Barabási
December 2020, Virus research,
Deisy Morselli Gysi, and Ítalo do Valle, and Marinka Zitnik, and Asher Ameli, and Xiao Gan, and Onur Varol, and Susan Dina Ghiassian, and J J Patten, and Robert A Davey, and Joseph Loscalzo, and Albert-László Barabási
January 2021, Frontiers in pharmacology,
Copied contents to your clipboard!